表紙
市場調查報告書
商品編碼
1029932

歐洲亨特綜合症治療的全球市場——2028 年的行業趨勢和預測

Europe Hunter Syndrome Treatment Market- Industry Trends and Forecast to 2028

出版日期: | 出版商: Data Bridge Market Research Private Limited | 英文 160 Pages | 商品交期: 3-5個工作天內

價格
  • 全貌
  • 簡介
  • 目錄
簡介

預計從 2021 年到 2028 年,全球歐洲亨特綜合症治療市場將以 3.2% 的複合年增長率增長。

本報告調查並分析了全球歐洲亨特綜合症治療市場,包括新治療、監管指南 (MPS II)、促進因素、抑制因素、市場機會、COVID-19 影響和嚴重程度。我們按類型、併發症提供市場信息、最終用戶、分銷渠道、區域市場信息、企業狀況、SWOT 分析和企業概況。

目錄

第 1 章介紹

第 2 章市場細分

第 3 章執行摘要

第 4 章重要考慮事項

第 5 章 Hunter 綜合徵的新療法

  • 處理:DNL310
  • 處理:JR141
  • 處理:TAK-609/SHP609/HGT-2310
  • 處理:RGX-121
  • 處理:SB-913
  • 處理:AVR-RD-05
  • 治療:ODIPARCIL
  • 處理:AGT-181
  • 處理:EGT-301

亨特綜合徵(MPS II)第 6 章監管指南

  • 亨特綜合症:美國監管框架
  • 亨特綜合症:歐洲監管框架
  • Hunter Syndrome:亞太地區監管框架

第 7 章流行病學

第 8 章市場概覽

  • 促進因素
    • 亨特綜合徵患病率增加
    • 越來越多地採用基因療法
    • 加大政府工作力度
    • 增加公共和私營部門的資金
    • 技術進步
  • 抑製器
    • 目前治療的副作用
    • 政府對 MPSII 治療開發的嚴格規定
    • 人們對亨特綜合症的存在缺乏認識
    • 與 MPS II 治療相關的高成本
  • 市場機會
    • 對疾病特異性治療的高需求
    • 大公司合作、併購
    • 新途徑藥物的存在
  • 挑戰
    • 當前的治療限制
  • 不當的兌換政策

第 9 章歐洲亨特綜合徵治療市場:COVID-19 的影響

  • 對價格的影響
  • 對需求的影響
  • 對供應鏈的影響
  • 製造商的戰略決策
  • 結論

第 10 章歐洲亨特綜合徵治療市場:按嚴重程度

  • 概述
  • 中度至重度
  • 輕度至中度

第 11 章歐洲亨特綜合徵治療市場:按類型

  • 概述
  • □替代療法
    • ELAPRASE + TAK-609
    • 漢特□
    • 伊茲卡戈
  • 幹細胞移植
    • 臍帶移植
    • 骨髓移植
  • 手術治療
    • 心臟瓣膜置換術
    • 氣管切開術
    • 氣道正壓裝置
    • 關節攣縮
    • 腹疝手術
    • 其他
  • 其他

第 12 章歐洲亨特綜合徵治療市場:併發症

  • 概述
  • 呼吸系統疾病
  • 神經紊亂
  • 心血管
  • 肌肉骨骼
  • 胃腸道疾病
  • 眼科
  • 聽力學
  • 牙科
  • 其他

第 13 章歐洲亨特綜合徵治療市場:按最終用戶

  • 概述
  • 醫院
  • 診所
  • 醫療保健
  • 其他

第 14 章歐洲亨特綜合徵治療市場:按分銷渠道

  • 概述
  • 醫院藥房
  • 零售藥店
  • 網上藥店
  • 其他

第 15 章歐洲亨特綜合徵治療市場:按地區

  • 歐洲
    • 德國
    • 法國
    • 英國
    • 意大利
    • 西班牙
    • 荷蘭
    • 俄羅斯
    • 瑞士
    • 土耳其
    • 奧地利
    • 挪威
    • 匈牙利
    • 立陶宛
    • 波蘭
    • 愛爾蘭
    • 其他歐洲

第 16 章歐洲亨特綜合徵治療市場:企業現狀

  • 公司份額分析:歐洲

第17章SWOT分析

第18章公司簡介

  • TAKEDA PHARMACEUTICAL COMPANY LIMITED
  • GREEN CROSS CORP.
  • ABBOTT
  • AVROBIO, INC.
  • BD
  • CANBRIDGE LIFE SCIENCES LTD.
  • DENALI THERAPEUTICS
  • HOMOLOGY MEDICINES, INC.
  • INVENTIVA
  • JASPER THERAPEUTICS, INC.
  • JCR PHARMACEUTICALS CO., LTD.
  • JOHNSON & JOHNSONS SERVICES, INC.
  • MEDTRONIC
  • NOVARTIS AG
  • ON-X LIFE TECHNOLOGIES(A SUBSIDIARY OF CRYOLIFE, INC.)
  • PFIZER INC.
  • REGENXBIO INC.
  • SANGAMO THERAPEUTICS
  • STRYKER
  • UCB S.A.

第 19 章問卷

第20章相關報導

目錄

Europe hunter syndrome treatment market is projected to register a healthy CAGR of 3.2% in the forecast period of 2021 to 2028. The new market report contains data for the historic year 2019, the base year of calculation is 2020 and the forecast period is 2021 to 2028.

Market Players:

Europe Hunter Syndrome Treatment Market, By Severity (Mild to Moderate, Moderate to Severe), Type (Enzyme Replacement Therapy (ERT), Stem Cell Transplant, Surgical Treatment, Others), Complications (Respiratory Disorders, Neurological Disorders, Gastrointestinal Disorders, Cardiovascular, Ophthalmic, Audiologic, Dental, Musculoskeletal, Others), End User (Hospitals, Clinics, Home Healthcare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others), Country (Germany, U.K., France, Italy, Spain, Netherlands, Russia, Switzerland, Belgium, Turkey, Austria, Norway, Hungary, Lithuania, Ireland, Poland, and Rest of Europe) Industry Trends and Forecast to 2028

Some of the major factors contributing to the growth of Europe hunter syndrome treatment market are:

  • Increasing prevalence of hunter syndrome
  • Rising adoption of gene therapy
  • Increasing government initiatives

Market Players:

The key market players for Europe hunter syndrome treatment market are listed below:

  • Pfizer Inc.
  • Takeda Pharmaceutical Company Limited
  • Medtronic
  • Abbott
  • On-X Life Technologies (a subsidiary of CryoLife, Inc.)
  • BD
  • Medical Device Business Services Inc.
  • Stryker
  • UCB S.A
  • Novartis AG
  • Sangamo Therapeutics
  • AVROBIO Inc.
  • Denali Therapeutics
  • Inventiva
  • Johnson & Johnson Services, Inc.

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 OBJECTIVES OF THE STUDY
  • 1.2 MARKET DEFINITION
  • 1.3 OVERVIEW OF EUROPE HUNTER SYNDROME TREATMENT MARKET
  • 1.4 LIMITATIONS
  • 1.5 MARKETS COVERED

2 MARKET SEGMENTATION

  • 2.1 MARKETS COVERED
  • 2.2 GEOGRAPHICAL SCOPE
  • 2.3 YEARS CONSIDERED FOR THE STUDY
  • 2.4 CURRENCY AND PRICING
  • 2.5 DBMR TRIPOD DATA VALIDATION MODEL
  • 2.6 MULTIVARIATE MODELLING
  • 2.7 SEVERITY LIFELINE CURVE
  • 2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
  • 2.9 DBMR MARKET POSITION GRID
  • 2.10 MARKET END USER COVERAGE GRID
  • 2.11 VENDOR SHARE ANALYSIS
  • 2.12 SECONDARY SOURCES
  • 2.13 ASSUMPTIONS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

5 EMERGING TREATMENTS FOR HUNTER SYNDROME

  • 5.1 TREATMENT: DNL310
  • 5.2 TREATMENT: JR141
  • 5.3 TREATMENT: TAK-609/SHP609/HGT-2310
  • 5.4 TREATMENT: RGX-121
  • 5.5 TREATMENT: SB-913
  • 5.6 TREATMENT: AVR-RD-05
  • 5.7 TREATMENT: ODIPARCIL
  • 5.8 TREATMENT: AGT-181
  • 5.9 TREATMENT: EGT-301

6 REGULATORY GUIDELINES FOR HUNTER SYNDROME (MPS II)

  • 6.1 U.S REGULATORY FRAMEWORK FOR HUNTER SYNDROME
  • 6.2 EUROPE REGULATORY FRAMEWORK FOR HUNTER SYNDROME
  • 6.3 ASIA-PACIFIC REGULATORY FRAMEWORK FOR HUNTER SYNDROME

7 EPIDEMIOLOGY

8 MARKET OVERVIEW

  • 8.1 DRIVERS
    • 8.1.1 INCREASING PREVALENCE OF HUNTER SYNDROME
    • 8.1.2 RISING ADOPTION OF GENE THERAPY
    • 8.1.3 INCREASING GOVERNMENT INITIATIVES
    • 8.1.4 INCREASING FUND BY PUBLIC AND PRIVATE ORGANISATIONS
    • 8.1.5 TECHNOLOGICAL ADVANCEMENTS
  • 8.2 RESTRAINTS
    • 8.2.1 ADVERSE EFFECTS OF CURRENT TREATMENTS
    • 8.2.2 STRINGENT GOVERNMENT REGULATIONS FOR MPS II TREATMENT DEVELOPMENT
    • 8.2.3 UNAWARENESS AMONG PEOPLE OF THE EXISTENCE OF HUNTER SYNDROME
    • 8.2.4 HIGH COST ASSOCIATED WITH TREATMENT OF MPS II
  • 8.3 OPPORTUNITIES
    • 8.3.1 HIGH DEMAND OF DISEASE-SPECIFIC TREATMENT
    • 8.3.2 RISING COLLABORATIONS, AND MERGERS & ACQUISITIONS AMONG THE MARKET PLAYERS
    • 8.3.3 PRESENCE OF NOVEL PIPELINE DRUGS
  • 8.4 CHALLENGES
    • 8.4.1 LIMITATIONS OF CURRENT TREATMENT
  • 8.5 IMPROPER REIMBURSEMENT POLICIES

9 IMPACT OF COVID-19 ON THE EUROPE HUNTER SYNDROME TREATMENT MARKET

  • 9.1 IMPACT ON PRICE
  • 9.2 IMPACT ON DEMAND
  • 9.3 IMPACT ON SUPPLY CHAIN
  • 9.4 STRATEGIC DECISIONS FOR MANUFACTURERS
  • 9.5 CONCLUSION

10 EUROPE HUNTER SYNDROME TREATMENT MARKET, BY SEVERITY

  • 10.1 OVERVIEW
  • 10.2 MODERATE TO SEVERE
  • 10.3 MILD TO MODERATE

11 EUROPE HUNTER SYNDROME TREATMENT MARKET, BY TYPE

  • 11.1 OVERVIEW
  • 11.2 ENZYME REPLACEMENT THERAPY
    • 11.2.1 ELAPRASE + TAK-609
    • 11.2.2 HUNTERASE
    • 11.2.3 IZCARGO
  • 11.3 STEM CELL TRANSPLANT
    • 11.3.1 UMBILICAL CORD TRANSPLANT
    • 11.3.2 BONE MARROW TRANSPLANT
  • 11.4 SURGICAL TREATMENT
    • 11.4.1 CARDIAC VALVE REPLACEMENT SURGERY
    • 11.4.2 TRACHEOSTOMY
    • 11.4.3 POSITIVE AIRWAY PRESSURE DEVICES
    • 11.4.4 JOINT CONTRACTURES
    • 11.4.5 ABDOMINAL HERNIA SURGERY
    • 11.4.6 OTHERS
  • 11.5 OTHERS

12 EUROPE HUNTER SYNDROME TREATMENT MARKET, BY COMPLICATIONS

  • 12.1 OVERVIEW
  • 12.2 RESPIRATORY DISORDERS
  • 12.3 NEUROLOGICAL DISORDERS
  • 12.4 CARDIOVASCULAR
  • 12.5 MUSCULOSKELETAL
  • 12.6 GASTROINTESTINAL DISORDERS
  • 12.7 OPHTHALMIC
  • 12.8 AUDIOLOGIC
  • 12.9 DENTAL
  • 12.10 OTHERS

13 EUROPE HUNTER SYNDROME TREATMENT MARKET, BY END USER

  • 13.1 OVERVIEW
  • 13.2 HOSPITALS
  • 13.3 CLINICS
  • 13.4 HOME HEALTHCARE
  • 13.5 OTHERS

14 EUROPE HUNTER SYNDROME TREATMENT MARKET, BY DISTRIBUTION CHANNEL

  • 14.1 OVERVIEW
  • 14.2 HOSPITAL PHARMACY
  • 14.3 RETAIL PHARMACY
  • 14.4 ONLINE PHARMACY
  • 14.5 OTHERS

15 EUROPE HUNTER SYNDROME TREATMENT MARKET, BY REGION

  • 15.1 EUROPE
    • 15.1.1 GERMANY
    • 15.1.2 FRANCE
    • 15.1.3 U.K.
    • 15.1.4 ITALY
    • 15.1.5 SPAIN
    • 15.1.6 NETHERLANDS
    • 15.1.7 RUSSIA
    • 15.1.8 SWITZERLAND
    • 15.1.9 TURKEY
    • 15.1.10 AUSTRIA
    • 15.1.11 NORWAY
    • 15.1.12 HUNGARY
    • 15.1.13 LITHUANIA
    • 15.1.14 POLAND
    • 15.1.15 IRELAND
    • 15.1.16 REST OF EUROPE

16 EUROPE HUNTER SYNDROME TREATMENT MARKET: COMPANY LANDSCAPE

  • 16.1 COMPANY SHARE ANALYSIS: EUROPE

17 SWOT ANALYSIS

18 COMPANY PROFILE

  • 18.1 TAKEDA PHARMACEUTICAL COMPANY LIMITED
    • 18.1.1 COMPANY SNAPSHOT
    • 18.1.2 REVENUE ANALYSIS
    • 18.1.3 COMPANY SHARE ANALYSIS
    • 18.1.4 PRODUCT PORTFOLIO
    • 18.1.5 RECENT DEVELOPMENTS
  • 18.2 GREEN CROSS CORP.
    • 18.2.1 COMPANY SNAPSHOT
    • 18.2.2 REVENUE ANALYSIS
    • 18.2.3 COMPANY SHARE ANALYSIS
    • 18.2.4 PRODUCT PORTFOLIO
    • 18.2.5 RECENT DEVELOPMENT
  • 18.3 ABBOTT
    • 18.3.1 COMPANY SNAPSHOT
    • 18.3.2 REVENUE ANALYSIS
    • 18.3.3 PRODUCT PORTFOLIO
    • 18.3.4 RECENT DEVELOPMENTS
  • 18.4 AVROBIO, INC.
    • 18.4.1 COMPANY SNAPSHOT
    • 18.4.2 PRODUCT PORTFOLIO
    • 18.4.3 RECENT DEVELOPMENTS
  • 18.5 BD
    • 18.5.1 COMPANY SNAPSHOT
    • 18.5.2 REVENUE ANALYSIS
    • 18.5.3 PRODUCT PORTFOLIO
    • 18.5.4 RECENT DEVELOPMENT
  • 18.6 CANBRIDGE LIFE SCIENCES LTD.
    • 18.6.1 COMPANY SNAPSHOT
    • 18.6.2 PRODUCT PORTFOLIO
    • 18.6.3 RECENT DEVELOPMENTS
  • 18.7 DENALI THERAPEUTICS
    • 18.7.1 COMPANY SNAPSHOT
    • 18.7.2 REVENUE ANALYSIS
    • 18.7.3 PRODUCT PORTFOLIO
    • 18.7.4 RECENT DEVELOPMENTS
  • 18.8 HOMOLOGY MEDICINES, INC.
    • 18.8.1 COMPANY SNAPSHOT
    • 18.8.2 REVENUE ANALYSIS
    • 18.8.3 TECHNOLOGY PORTFOLIO
    • 18.8.4 RECENT DEVELOPMENTS
  • 18.9 INVENTIVA
    • 18.9.1 COMPANY SNAPSHOT
    • 18.9.2 REVENUE ANALYSIS
    • 18.9.3 PRODUCT PORTFOLIO
    • 18.9.4 RECENT DEVELOPMENTS
  • 18.10 JASPER THERAPEUTICS, INC.
    • 18.10.1 COMPANY SNAPSHOT
    • 18.10.2 PRODUCT PORTFOLIO
    • 18.10.3 RECENT DEVELOPMENT
  • 18.11 JCR PHARMACEUTICALS CO., LTD.
    • 18.11.1 COMPANY SNAPSHOT
    • 18.11.2 REVENUE ANALYSIS
    • 18.11.3 PRODUCT PORTFOLIO
    • 18.11.4 RECENT DEVELOPMENTS
  • 18.12 JOHNSON & JOHNSONS SERVICES, INC.
    • 18.12.1 COMPANY SNAPSHOT
    • 18.12.2 REVENUE ANALYSIS
    • 18.12.3 PRODUCT PORTFOLIO
    • 18.12.4 RECENT DEVELOPMENTS
  • 18.13 MEDTRONIC
    • 18.13.1 COMPANY SNAPSHOT
    • 18.13.2 REVENUE ANALYSIS
    • 18.13.3 PRODUCT PORTFOLIO
    • 18.13.4 RECENT DEVELOPMENTS
  • 18.14 NOVARTIS AG
    • 18.14.1 COMPANY SNAPSHOT
    • 18.14.2 REVENUE ANALYSIS
    • 18.14.3 PRODUCT PORTFOLIO
    • 18.14.4 RECENT DEVELOPMENTS
  • 18.15 ON-X LIFE TECHNOLOGIES (A SUBSIDIARY OF CRYOLIFE, INC.)
    • 18.15.1 COMPANY SNAPSHOT
    • 18.15.2 REVENUE ANALYSIS
    • 18.15.3 PRODUCT PORTFOLIO
    • 18.15.4 RECENT DEVELOPMENTS
  • 18.16 PFIZER INC.
    • 18.16.1 COMPANY SNAPSHOT
    • 18.16.2 REVENUE ANALYSIS
    • 18.16.3 PRODUCT PORTFOLIO
    • 18.16.4 RECENT DEVELOPMENTS
  • 18.17 REGENXBIO INC.
    • 18.17.1 COMPANY SNAPSHOT
    • 18.17.2 REVENUE ANALYSIS
    • 18.17.3 PRODUCT PORTFOLIO
    • 18.17.4 RECENT DEVELOPMENTS
  • 18.18 SANGAMO THERAPEUTICS
    • 18.18.1 COMPANY SNAPSHOT
    • 18.18.2 REVENUE ANALYSIS
    • 18.18.3 PRODUCT PORTFOLIO
    • 18.18.4 RECENT DEVELOPMENT
  • 18.19 STRYKER
    • 18.19.1 COMPANY SNAPSHOT
    • 18.19.2 REVENUE ANALYSIS
    • 18.19.3 PRODUCT PORTFOLIO
    • 18.19.4 RECENT DEVELOPMENTS
  • 18.20 UCB S.A.
    • 18.20.1 COMPANY SNAPSHOT
    • 18.20.2 REVENUE ANALYSIS
    • 18.20.3 PRODUCT PORTFOLIO
    • 18.20.4 RECENT DEVELOPMENTS

19 QUESTIONNAIRE

20 RELATED REPORTS

LIST OF TABLES

  • TABLE 1 EUROPE HUNTER SYNDROME TREATMENT MARKET, BY SEVERITY, 2019-2028 (USD MILLION)
  • TABLE 2 EUROPE MODERATE TO SEVERE IN HUNTER SYNDROME TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)
  • TABLE 3 EUROPE MILD TO MODERATE IN EUROPE HUNTER SYNDROME TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)
  • TABLE 4 EUROPE HUNTER SYNDROME TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
  • TABLE 5 EUROPE ENZYME REPLACEMENT THERAPY (ERT) IN HUNTER SYNDROME TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)
  • TABLE 6 EUROPE ENZYME REPLACEMENT THERAPY (ERT) IN HUNTER SYNDROME TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
  • TABLE 7 EUROPE STEM CELL TRANSPLANT IN HUNTER SYNDROME TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)
  • TABLE 8 EUROPE STEM CELL TRANSPLANT IN HUNTER SYNDROME TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
  • TABLE 9 EUROPE SURGICAL TREATMENT IN HUNTER SYNDROME TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)
  • TABLE 10 EUROPE SURGICAL TREATMENT IN HUNTER SYNDROME TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
  • TABLE 11 EUROPE OTHERS IN HUNTER SYNDROME TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)
  • TABLE 12 EUROPE HUNTER SYNDROME TREATMENT MARKET, BY COMPLICATIONS, 2019-2028 (USD MILLION)
  • TABLE 13 EUROPE RESPIRATORY DISORDERS IN HUNTER SYNDROME TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)
  • TABLE 14 EUROPE NEUROLOGICAL DISORDERS IN HUNTER SYNDROME TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)
  • TABLE 15 EUROPE CARDIOVASCULAR IN HUNTER SYNDROME TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)
  • TABLE 16 EUROPE MUSCULOSKELETAL IN HUNTER SYNDROME TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)
  • TABLE 17 EUROPE GASTROINTESTINAL DISORDERS IN HUNTER SYNDROME TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)
  • TABLE 18 EUROPE OPHTHALMIC IN HUNTER SYNDROME TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)
  • TABLE 19 EUROPE AUDIOLOGIC IN HUNTER SYNDROME TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)
  • TABLE 20 EUROPE DENTAL IN HUNTER SYNDROME TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)
  • TABLE 21 EUROPE OTHERS IN HUNTER SYNDROME TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)
  • TABLE 22 EUROPE HUNTER SYNDROME TREATMENT MARKET: BY END USER, 2020
  • TABLE 23 EUROPE HOSPITALS IN HUNTER SYNDROME TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)
  • TABLE 24 EUROPE CLINICS IN HUNTER SYNDROME TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)
  • TABLE 25 EUROPE HOME HEALTHCARE IN HUNTER SYNDROME TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)
  • TABLE 26 EUROPE OTHERS IN HUNTER SYNDROME TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)
  • TABLE 27 EUROPE HUNTER SYNDROME TREATMENT MARKET: BY DISTRIBUTION CHANNEL, 2020
  • TABLE 28 EUROPE HOSPITAL PHARMACY IN HUNTER SYNDROME TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)
  • TABLE 29 EUROPE RETAIL PHARMACY IN HUNTER SYNDROME MARKET, BY REGION, 2019-2028 (USD MILLION)
  • TABLE 30 EUROPE ONLINE PHARMACY IN HUNTER SYNDROME TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)
  • TABLE 31 EUROPE OTHERS IN HUNTER SYNDROME TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)
  • TABLE 32 EUROPE HUNTER SYNDROME TREATMENT MARKET, BY COUNTRY, 2019-2028 (USD MILLION)
  • TABLE 33 EUROPE HUNTER SYNDROME TREATMENT MARKET, BY SEVERITY, 2019-2028 (USD MILLION)
  • TABLE 34 EUROPE HUNTER SYNDROME TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
  • TABLE 35 EUROPE ENZYME REPLACEMENT THERAPY (ERT) IN HUNTER SYNDROME TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
  • TABLE 36 EUROPE STEM CELL TRANSPLANT IN HUNTER SYNDROME TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
  • TABLE 37 EUROPE SURGICAL TREATMENT IN HUNTER SYNDROME TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
  • TABLE 38 EUROPE HUNTER SYNDROME TREATMENT MARKET, BY COMPLICATIONS, 2019-2028 (USD MILLION)
  • TABLE 39 EUROPE HUNTER SYNDROME TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION)
  • TABLE 40 EUROPE HUNTER SYNDROME TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
  • TABLE 41 GERMANY HUNTER SYNDROME TREATMENT MARKET, BY SEVERITY, 2019-2028 (USD MILLION)
  • TABLE 42 GERMANY HUNTER SYNDROME TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
  • TABLE 43 GERMANY ENZYME REPLACEMENT THERAPY (ERT) IN HUNTER SYNDROME TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
  • TABLE 44 GERMANY STEM CELL TRANSPLANT IN HUNTER SYNDROME TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
  • TABLE 45 GERMANY SURGICAL TREATMENT IN HUNTER SYNDROME TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
  • TABLE 46 GERMANY HUNTER SYNDROME TREATMENT MARKET, BY COMPLICATIONS, 2019-2028 (USD MILLION)
  • TABLE 47 GERMANY HUNTER SYNDROME TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION)
  • TABLE 48 GERMANY HUNTER SYNDROME TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
  • TABLE 49 FRANCE HUNTER SYNDROME TREATMENT MARKET, BY SEVERITY, 2019-2028 (USD MILLION)
  • TABLE 50 FRANCE HUNTER SYNDROME TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
  • TABLE 51 FRANCE ENZYME REPLACEMENT THERAPY (ERT) IN HUNTER SYNDROME TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
  • TABLE 52 FRANCE STEM CELL TRANSPLANT IN HUNTER SYNDROME TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
  • TABLE 53 FRANCE SURGICAL TREATMENT IN HUNTER SYNDROME TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
  • TABLE 54 FRANCE HUNTER SYNDROME TREATMENT MARKET, BY COMPLICATIONS, 2019-2028 (USD MILLION)
  • TABLE 55 FRANCE HUNTER SYNDROME TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION)
  • TABLE 56 FRANCE HUNTER SYNDROME TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
  • TABLE 57 U.K. HUNTER SYNDROME TREATMENT MARKET, BY SEVERITY, 2019-2028 (USD MILLION)
  • TABLE 58 U.K. HUNTER SYNDROME TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
  • TABLE 59 U.K. ENZYME REPLACEMENT THERAPY (ERT) IN HUNTER SYNDROME TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
  • TABLE 60 U.K. STEM CELL TRANSPLANT IN HUNTER SYNDROME TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
  • TABLE 61 U.K. SURGICAL TREATMENT IN HUNTER SYNDROME TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
  • TABLE 62 U.K. HUNTER SYNDROME TREATMENT MARKET, BY COMPLICATIONS, 2019-2028 (USD MILLION)
  • TABLE 63 U.K. HUNTER SYNDROME TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION)
  • TABLE 64 U.K. HUNTER SYNDROME TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
  • TABLE 65 ITALY HUNTER SYNDROME TREATMENT MARKET, BY SEVERITY, 2019-2028 (USD MILLION)
  • TABLE 66 ITALY HUNTER SYNDROME TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
  • TABLE 67 ITALY ENZYME REPLACEMENT THERAPY (ERT) IN HUNTER SYNDROME TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
  • TABLE 68 ITALY STEM CELL TRANSPLANT IN HUNTER SYNDROME TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
  • TABLE 69 ITALY SURGICAL TREATMENT IN HUNTER SYNDROME TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
  • TABLE 70 ITALY HUNTER SYNDROME TREATMENT MARKET, BY COMPLICATIONS, 2019-2028 (USD MILLION)
  • TABLE 71 ITALY HUNTER SYNDROME TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION)
  • TABLE 72 ITALY HUNTER SYNDROME TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
  • TABLE 73 SPAIN HUNTER SYNDROME TREATMENT MARKET, BY SEVERITY, 2019-2028 (USD MILLION)
  • TABLE 74 SPAIN HUNTER SYNDROME TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
  • TABLE 75 SPAIN ENZYME REPLACEMENT THERAPY (ERT) IN HUNTER SYNDROME TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
  • TABLE 76 SPAIN STEM CELL TRANSPLANT IN HUNTER SYNDROME TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
  • TABLE 77 SPAIN SURGICAL TREATMENT IN HUNTER SYNDROME TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
  • TABLE 78 SPAIN HUNTER SYNDROME TREATMENT MARKET, BY COMPLICATIONS, 2019-2028 (USD MILLION)
  • TABLE 79 SPAIN HUNTER SYNDROME TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION)
  • TABLE 80 SPAIN HUNTER SYNDROME TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
  • TABLE 81 NETHERLANDS HUNTER SYNDROME TREATMENT MARKET, BY SEVERITY, 2019-2028 (USD MILLION)
  • TABLE 82 NETHERLANDS HUNTER SYNDROME TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
  • TABLE 83 NETHERLANDS ENZYME REPLACEMENT THERAPY (ERT) IN HUNTER SYNDROME TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
  • TABLE 84 NETHERLANDS STEM CELL TRANSPLANT IN HUNTER SYNDROME TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
  • TABLE 85 NETHERLANDS SURGICAL TREATMENT IN HUNTER SYNDROME TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
  • TABLE 86 NETHERLANDS HUNTER SYNDROME TREATMENT MARKET, BY COMPLICATIONS, 2019-2028 (USD MILLION)
  • TABLE 87 NETHERLANDS HUNTER SYNDROME TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION)
  • TABLE 88 NETHERLANDS HUNTER SYNDROME TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
  • TABLE 89 RUSSIA HUNTER SYNDROME TREATMENT MARKET, BY SEVERITY, 2019-2028 (USD MILLION)
  • TABLE 90 RUSSIA HUNTER SYNDROME TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
  • TABLE 91 RUSSIA ENZYME REPLACEMENT THERAPY (ERT) IN HUNTER SYNDROME TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
  • TABLE 92 RUSSIA STEM CELL TRANSPLANT IN HUNTER SYNDROME TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
  • TABLE 93 RUSSIA SURGICAL TREATMENT IN HUNTER SYNDROME TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
  • TABLE 94 RUSSIA HUNTER SYNDROME TREATMENT MARKET, BY COMPLICATIONS, 2019-2028 (USD MILLION)
  • TABLE 95 RUSSIA HUNTER SYNDROME TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION)
  • TABLE 96 RUSSIA HUNTER SYNDROME TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
  • TABLE 97 SWITZERLAND HUNTER SYNDROME TREATMENT MARKET, BY SEVERITY, 2019-2028 (USD MILLION)
  • TABLE 98 SWITZERLAND HUNTER SYNDROME TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
  • TABLE 99 SWITZERLAND ENZYME REPLACEMENT THERAPY (ERT) IN HUNTER SYNDROME TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
  • TABLE 100 SWITZERLAND STEM CELL TRANSPLANT IN HUNTER SYNDROME TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
  • TABLE 101 SWITZERLAND SURGICAL TREATMENT IN HUNTER SYNDROME TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
  • TABLE 102 SWITZERLAND HUNTER SYNDROME TREATMENT MARKET, BY COMPLICATIONS, 2019-2028 (USD MILLION)
  • TABLE 103 SWITZERLAND HUNTER SYNDROME TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION)
  • TABLE 104 SWITZERLAND HUNTER SYNDROME TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
  • TABLE 105 TURKEY HUNTER SYNDROME TREATMENT MARKET, BY SEVERITY, 2019-2028 (USD MILLION)
  • TABLE 106 TURKEY HUNTER SYNDROME TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
  • TABLE 107 TURKEY ENZYME REPLACEMENT THERAPY (ERT) IN HUNTER SYNDROME TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
  • TABLE 108 TURKEY STEM CELL TRANSPLANT IN HUNTER SYNDROME TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
  • TABLE 109 TURKEY SURGICAL TREATMENT IN HUNTER SYNDROME TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
  • TABLE 110 TURKEY HUNTER SYNDROME TREATMENT MARKET, BY COMPLICATIONS, 2019-2028 (USD MILLION)
  • TABLE 111 TURKEY HUNTER SYNDROME TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION)
  • TABLE 112 TURKEY HUNTER SYNDROME TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
  • TABLE 113 AUSTRIA HUNTER SYNDROME TREATMENT MARKET, BY SEVERITY, 2019-2028 (USD MILLION)
  • TABLE 114 AUSTRIA HUNTER SYNDROME TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
  • TABLE 115 AUSTRIA ENZYME REPLACEMENT THERAPY (ERT) IN HUNTER SYNDROME TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
  • TABLE 116 AUSTRIA STEM CELL TRANSPLANT IN HUNTER SYNDROME TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
  • TABLE 117 AUSTRIA SURGICAL TREATMENT IN HUNTER SYNDROME TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
  • TABLE 118 AUSTRIA HUNTER SYNDROME TREATMENT MARKET, BY COMPLICATIONS, 2019-2028 (USD MILLION)
  • TABLE 119 AUSTRIA HUNTER SYNDROME TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION)
  • TABLE 120 AUSTRIA HUNTER SYNDROME TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
  • TABLE 121 NORWAY HUNTER SYNDROME TREATMENT MARKET, BY SEVERITY, 2019-2028 (USD MILLION)
  • TABLE 122 NORWAY HUNTER SYNDROME TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
  • TABLE 123 NORWAY ENZYME REPLACEMENT THERAPY (ERT) IN HUNTER SYNDROME TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
  • TABLE 124 NORWAY STEM CELL TRANSPLANT IN HUNTER SYNDROME TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
  • TABLE 125 NORWAY SURGICAL TREATMENT IN HUNTER SYNDROME TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
  • TABLE 126 NORWAY HUNTER SYNDROME TREATMENT MARKET, BY COMPLICATIONS, 2019-2028 (USD MILLION)
  • TABLE 127 NORWAY HUNTER SYNDROME TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION)
  • TABLE 128 NORWAY HUNTER SYNDROME TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
  • TABLE 129 HUNGARY HUNTER SYNDROME TREATMENT MARKET, BY SEVERITY, 2019-2028 (USD MILLION)
  • TABLE 130 HUNGARY HUNTER SYNDROME TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
  • TABLE 131 HUNGARY ENZYME REPLACEMENT THERAPY (ERT) IN HUNTER SYNDROME TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
  • TABLE 132 HUNGARY STEM CELL TRANSPLANT IN HUNTER SYNDROME TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
  • TABLE 133 HUNGARY SURGICAL TREATMENT IN HUNTER SYNDROME TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
  • TABLE 134 HUNGARY HUNTER SYNDROME TREATMENT MARKET, BY COMPLICATIONS, 2019-2028 (USD MILLION)
  • TABLE 135 HUNGARY HUNTER SYNDROME TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION)
  • TABLE 136 HUNGARY HUNTER SYNDROME TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
  • TABLE 137 LITHUANIA HUNTER SYNDROME TREATMENT MARKET, BY SEVERITY, 2019-2028 (USD MILLION)
  • TABLE 138 LITHUANIA HUNTER SYNDROME TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
  • TABLE 139 LITHUANIA ENZYME REPLACEMENT THERAPY (ERT) IN HUNTER SYNDROME TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
  • TABLE 140 LITHUANIA STEM CELL TRANSPLANT IN HUNTER SYNDROME TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
  • TABLE 141 LITHUANIA SURGICAL TREATMENT IN HUNTER SYNDROME TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
  • TABLE 142 LITHUANIA HUNTER SYNDROME TREATMENT MARKET, BY COMPLICATIONS, 2019-2028 (USD MILLION)
  • TABLE 143 LITHUANIA HUNTER SYNDROME TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION)
  • TABLE 144 LITHUANIA HUNTER SYNDROME TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
  • TABLE 145 POLAND HUNTER SYNDROME TREATMENT MARKET, BY SEVERITY, 2019-2028 (USD MILLION)
  • TABLE 146 POLAND HUNTER SYNDROME TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
  • TABLE 147 POLAND ENZYME REPLACEMENT THERAPY (ERT) IN HUNTER SYNDROME TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
  • TABLE 148 POLAND STEM CELL TRANSPLANT IN HUNTER SYNDROME TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
  • TABLE 149 POLAND SURGICAL TREATMENT IN HUNTER SYNDROME TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
  • TABLE 150 POLAND HUNTER SYNDROME TREATMENT MARKET, BY COMPLICATIONS, 2019-2028 (USD MILLION)
  • TABLE 151 POLAND HUNTER SYNDROME TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION)
  • TABLE 152 POLAND HUNTER SYNDROME TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
  • TABLE 153 IRELAND HUNTER SYNDROME TREATMENT MARKET, BY SEVERITY, 2019-2028 (USD MILLION)
  • TABLE 154 IRELAND HUNTER SYNDROME TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
  • TABLE 155 IRELAND ENZYME REPLACEMENT THERAPY (ERT) IN HUNTER SYNDROME TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
  • TABLE 156 IRELAND STEM CELL TRANSPLANT IN HUNTER SYNDROME TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
  • TABLE 157 IRELAND SURGICAL TREATMENT IN HUNTER SYNDROME TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
  • TABLE 158 IRELAND HUNTER SYNDROME TREATMENT MARKET, BY COMPLICATIONS, 2019-2028 (USD MILLION)
  • TABLE 159 IRELAND HUNTER SYNDROME TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION)
  • TABLE 160 IRELAND HUNTER SYNDROME TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
  • TABLE 161 REST OF EUROPE HUNTER SYNDROME TREATMENT MARKET, BY SEVERITY, 2019-2028 (USD MILLION)

LIST OF FIGURES

  • FIGURE 1 EUROPE HUNTER SYNDROME TREATMENT MARKET : SEGMENTATION
  • FIGURE 2 EUROPE HUNTER SYNDROME TREATMENT MARKET : DATA TRIANGULATION
  • FIGURE 3 EUROPE HUNTER SYNDROME TREATMENT MARKET : DROC ANALYSIS
  • FIGURE 4 EUROPE HUNTER SYNDROME TREATMENT MARKET : EUROPE VS REGIONAL MARKET ANALYSIS
  • FIGURE 5 EUROPE HUNTER SYNDROME TREATMENT MARKET : COMPANY RESEARCH ANALYSIS
  • FIGURE 6 EUROPE HUNTER SYNDROME TREATMENT MARKET : INTERVIEW DEMOGRAPHICS
  • FIGURE 7 EUROPE HUNTER SYNDROME TREATMENT MARKET : DBMR MARKET POSITION GRID
  • FIGURE 8 EUROPE HUNTER SYNDROME TREATMENT MARKET : MARKET END USER COVERAGE GRID
  • FIGURE 9 EUROPE HUNTER SYNDROME TREATMENT MARKET : VENDOR SHARE ANALYSIS
  • FIGURE 10 EUROPE HUNTER SYNDROME TREATMENT MARKET : SEGMENTATION
  • FIGURE 11 INCREASING PREVALANCE OF HUNTER SYNDROME IS EXPECTED TO DRIVE THE EUROPE HUNTER SYNDROME TREATMENT MARKET IN THE FORECAST PERIOD OF 2021 TO 2028
  • FIGURE 12 MODERATE TO SEVERE SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE EUROPE HUNTER SYNDROME TREATMENT MARKET IN 2021 & 2028
  • FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES OF EUROPE HUNTER SYNDROME TREATMENT MARKET
  • FIGURE 14 EUROPE HUNTER SYNDROME TREATMENT MARKET: BY SEVERITY, 2020
  • FIGURE 17 EUROPE HUNTER SYNDROME TREATMENT MARKET: BY END USER, 2020
  • FIGURE 18 EUROPE HUNTER SYNDROME TREATMENT MARKET: BY DISTRIBUTION CHANNEL, 2020
  • FIGURE 19 EUROPE HUNTER SYNDROME TREATMENT MARKET: SNAPSHOT (2020)
  • FIGURE 20 EUROPE HUNTER SYNDROME TREATMENT MARKET: BY COUNTRY (2020)
  • FIGURE 21 EUROPE HUNTER SYNDROME TREATMENT MARKET: BY COUNTRY (2021 & 2028)
  • FIGURE 22 EUROPE HUNTER SYNDROME TREATMENT MARKET: BY COUNTRY (2020 & 2028)
  • FIGURE 23 EUROPE HUNTER SYNDROME TREATMENT MARKET: BY SEVERITY (2021-2028)
  • FIGURE 24 EUROPE HUNTER SYNDROME TREATMENT MARKET: COMPANY SHARE 2020 (%)